Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorLIMA, Vladmir C. Cordeiro de
dc.contributor.authorBALDOTTO, Clarissa S.
dc.contributor.authorBARRIOS, Carlos H.
dc.contributor.authorSOBRINHO, Eldsamira M.
dc.contributor.authorZUKIN, Mauro
dc.contributor.authorMATHIAS, Clarissa
dc.contributor.authorZAFFARONI, Facundo
dc.contributor.authorNERY, Rodrigo C.
dc.contributor.authorMADEIRA, Gabriel
dc.contributor.authorV, Alex Amadio
dc.contributor.authorCOELHO, Juliano C.
dc.contributor.authorGEIB, Guilherme
dc.contributor.authorSIMOES, Maria Fernanda
dc.contributor.authorJR, Gilberto Castro
dc.identifier.citationJOURNAL OF GLOBAL ONCOLOGY, v.4, 2018
dc.description.abstractPurpose Of newly diagnosed patients with non-small-cell lung cancer (NSCLC), stage III accounts for 30%. Most patients are treated with concurrent chemoradiation therapy, but the addition of consolidation chemotherapy (CC) is debatable. We examined the effect of CC in Brazilian patients with stage III NSCLC treated in routine clinical practice. Methods We retrospectively collected data for patients from five different Brazilian cancer institutions who had stage III NSCLC and who were treated with chemoradiation therapy followed or not by CC. Eligible patients were age 18 years or older and must have been treated with cisplatin-carboplatin plus etoposide, paclitaxel, or vinorelbine, concurrently with thoracic radiation therapy (RT). Patients treated with surgery or neoadjuvant chemotherapy were excluded. The primary end point was overall survival (OS). Associations between CC and clinical variables and demographics were evaluated by using Pearson's chi(2) test. Survival curves were calculated by using the Kaplan-Meier method and were compared using the log-rank test. Univariable and multivariable analysis used a Cox proportional hazards model. Results We collected data from 165 patients. Median age was 60 years. Most patients were male (69.1%), white (77.9%), current or former smokers (93.3%), and had stage IIIB disease (52.7%). Adenocarcinoma was the most common histology (47.9%). Weight loss of more than 5% was observed in 39.1% and Eastern Cooperative Oncology Group performance status of 2 was observed in 14.6%. The only variable associated with CC was T stage (P = .022). We observed no statistically significant difference in OS between patients treated or not with CC (P = .128). A total delivered RT dose >= 61 Gy was the only variable independently associated with improved survival (P = .012). Conclusion Brazilian patients with locally advanced NSCLC who were treated with standard treatment achieved OS similar to that reported in randomized trials. CC did not improve OS in patients with stage III NSCLC after concurrent chemoradiation therapy. An RT dose of less than 61 Gy had a negative effect on OS. (C) 2018 by American Society of Clinical Oncologyeng
dc.relation.ispartofJournal of Global Oncology
dc.subject.othertnm classificationeng
dc.subject.otherhoosier oncologyeng
dc.subject.otherchest radiationeng
dc.titleStage III Non-Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohorteng
dc.rights.holderCopyright AMER SOC CLINICAL ONCOLOGYeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng, Vladmir C. Cordeiro de:AC Camargo Canc Ctr, Rio De Janeiro, Brazil, Clarissa S.:Inst Nacl Canc, Rio De Janeiro, Brazil, Carlos H.:Latin Amer Cooporal Oncol Grp, Porto Alegre, RS, Brazil, Eldsamira M.:Nucleo Oncol Bahia, Salvador, BA, Brazil, Mauro:Inst Nacl Canc, Rio De Janeiro, Brazil, Clarissa:Nucleo Oncol Bahia, Salvador, BA, Brazil, Facundo:Latin Amer Cooporal Oncol Grp, Porto Alegre, RS, Brazil, Rodrigo C.:AC Camargo Canc Ctr, Rio De Janeiro, Brazil, Gabriel:Inst Nacl Canc, Rio De Janeiro, Brazil, Juliano C.:Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil, Guilherme:Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil, Maria Fernanda:Nucleo Oncol Bahia, Salvador, BA, Brazil
hcfmusp.relation.referenceAhn JS, 2015, J CLIN ONCOL, V33, P2660, DOI 10.1200/JCO.2014.60.0130eng
hcfmusp.relation.referenceAraujo LH, 2018, J BRAS PNEUMOL, V44, P55, DOI [10.1590/s1806-37562017000000135, 10.1590/S1806-37562017000000135]eng
hcfmusp.relation.referenceBradley JD, 2015, LANCET ONCOL, V16, P187, DOI 10.1016/S1470-2045(14)71207-0eng
hcfmusp.relation.referenceCancer Research UK, 2015, LUNG CANC INC STATeng
hcfmusp.relation.referenceCarter DL, 2012, CLIN LUNG CANCER, V13, P205, DOI 10.1016/j.cllc.2011.10.005eng
hcfmusp.relation.referenceChun SG, 2017, J CLIN ONCOL, V35, P56, DOI 10.1200/JCO.2016.69.1378eng
hcfmusp.relation.referenceCurran WJ, 2011, J NATL CANCER I, V103, P1452, DOI 10.1093/jnci/djr325eng
hcfmusp.relation.referenceDomingues PM, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0449-8eng
hcfmusp.relation.referenceFuruse K, 1999, J CLIN ONCOL, V17, P2692, DOI 10.1200/JCO.1999.17.9.2692eng
hcfmusp.relation.referenceGandara David R, 2003, J Clin Oncol, V21, P2004, DOI 10.1200/JCO.2003.04.197eng
hcfmusp.relation.referenceGoldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1aeng
hcfmusp.relation.referenceGoldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009eng
hcfmusp.relation.referenceHanna N, 2008, J CLIN ONCOL, V26, P5755, DOI 10.1200/JCO.2008.17.7840eng
hcfmusp.relation.referenceJalal SI, 2012, ANN ONCOL, V23, P1730, DOI 10.1093/annonc/mdr565eng
hcfmusp.relation.referenceJEREMIC B, 1995, J CLIN ONCOL, V13, P452, DOI 10.1200/JCO.1995.13.2.452eng
hcfmusp.relation.referenceKim MK, 2007, J THORAC ONCOL S, V2eng
hcfmusp.relation.referenceKoshy M, 2014, CLIN LUNG CANCER, V15, P365, DOI 10.1016/j.cllc.2014.05.004eng
hcfmusp.relation.referenceSantana-Davila R, 2015, J CLIN ONCOL, V33, P567, DOI 10.1200/JCO.2014.56.2587eng
hcfmusp.relation.referenceSCHAAKEKONING C, 1992, NEW ENGL J MED, V326, P524, DOI 10.1056/NEJM199202203260805eng
hcfmusp.relation.referenceSenan S, 2016, J CLIN ONCOL, V34, P953, DOI 10.1200/JCO.2015.64.8824eng
hcfmusp.relation.referenceTsujino K, 2013, J THORAC ONCOL, V8, P1181, DOI 10.1097/JTO.0b013e3182988348eng
hcfmusp.relation.referenceVokes EE, 2007, J CLIN ONCOL, V25, P1698, DOI 10.1200/JCO.2006.07.3569eng
hcfmusp.relation.referenceWorld Health Organization, CANC FACT SHEET 2018eng
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - LIM/24
LIM/24 - Laboratório de Oncologia Experimental

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar

Files in This Item:
File Description SizeFormat 
art_LIMA_Stage_III_NonSmallCell_Lung_Cancer_Treated_With_Concurrent_2018.PDFpublishedVersion (English)621.2 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.